Early-stage vaginal carcinoma - an analysis of 70 patients

Otton, Geoff; Nicklin, James L.; Dickie, Graeme; Niedetzky, Paul; Tripcony, Lee; Perrin, Lewis; Crandon, Alexander J.

doi:10.1111/j.1048-891x.2004.014214.x

Cited by 29 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCC of the vagina is the most common histological type, and its frequency is estimated at 85% [12][13][14]. Histological features of the patients enrolled in our study were consistent with the literature.…”

Section: Discussionsupporting

confidence: 88%

“…Although radiotherapy is recommended as the standard treatment for all stages in many centers, surgical treatment is a better solution for early-stage disease in terms of survival [15][16][17]. Radical hysterectomy, vaginectomy, and pelvic lymph node dissection are the current approaches to treating vaginal cancer [12,13,16,17]. Vaginal cancer management has not been standardized because prospective studies on the possible treatment of vaginal cancer have not been conducted.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective evaluation of clinical and pathological features, as well as diagnostic and treatment protocols of primary vaginal malignancy

Kulhan

Külhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Our study aimed to determine the epidemiological characteristics and diagnostic and treatment protocols of primary vaginal carcinoma. Also, we compared the clinical and pathological features of primary vaginal carcinoma which intersect with cervical and vulvar carcinomas. Results:The histological distribution of the 16 patients with primary vaginal carcinoma was as follows: 9 patients (56.3%) with squamous cell carcinoma (SCC), 5 (31.3%) with rhabdomyosarcoma, and 2 (12.5%) with adenocarcinoma. Conclusion:The stage of the disease was found the be the main factor affecting the survival.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of clinical and pathological features, as well as diagnostic and treatment protocols of primary vaginal malignancy

Kulhan

Külhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…Most of the reports in the literature consist of small, single institution retrospective series ranging from 70–314 patients(8, 13, 14). Additionally, due to the rarity of the disease, the case series presented reflect a long period of time with heterogeneous clinical data and treatment techniques.…”

Section: Discussionmentioning

confidence: 99%

Factors Affecting Risk of Mortality in Women With Vaginal Cancer

Shah

Goff

Lowe

et al. 2009

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Objective-To estimate the current effect of demographics, pathology, and treatment on mortality among women with vaginal cancer.Methods-Using data from 17 population-based cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program, 2,149 women diagnosed with primary vaginal cancer between 1990 to 2004 were identified. The association between various demographic factors, tumor characteristics, and treatments and risk of vaginal cancer mortality were evaluated using Cox proportional hazards modeling.Results-The mean age at diagnosis was 65.7 ± 14.3 years. Approximately 66% of all cases were non-Hispanic whites. Incidence was highest among African-American women (1.24/100,000 personyears). The 5-year disease specific-survival was 84% (Stage I), 75% (Stage II), and 57% (Stage III/ IV). In a multivariate adjusted model, women with tumors greater than 4 cm and advanced disease had elevated risks of mortality (HR 1.71, 4.67, respectively). Compared to women with squamous cell carcinomas, patients with vaginal melanoma had a 1.51-fold (95% CI: 1.07-2.41) increased risk of mortality. Surgery alone as a treatment modality had the lowest risk of mortality. The risk of mortality has decreased over time, as women diagnosed after 2000 had an adjusted 17% decrease in their risk of death compared to women from 1990-1994.Conclusion-Stage, tumor size, histology, and treatment modality significantly affect a woman's risk of mortality from vaginal cancer. There appears to be a survival advantage that is temporally related with the advent of chemoradiation.

show abstract

“…Because vaginal cancer is rare, treatment plans remain less well defined, often individualized and extrapolated from institutional experience and outcomes in cervical cancer. 1,[16][17][18][19] There is an increasing trend towards organ preservation and treatment strategies based on combined external beam radiation and brachytherapy, often with concurrent chemotherapy, 14,20,21 surgery being reserved for those with in situ or very early-stage disease. 22 Increasing utilization of MR may provide superior delineation of tumour volume, both for initial staging and follow-up, to allow for better treatment planning.…”

mentioning

confidence: 99%